LimmaTech Biologics, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, has in-licensed Shigella bioconjugate vaccine from GlaxoSmithKline Biologicals SA. The agreement enables the startup to further advance the vaccine into the Phase I/II study stage. Results are expected in 2023.
